A collective sigh of relief was heard across the world when Paxlovid, Pfizer Inc.’s co-packaged nirmatrelvir and ritonavir treatment for COVID-19, was launched. However, Twitter has been abuzz of late with news of the disease relapsing in a few individuals despite having taken the recommended five-day course of the drug.
COVID-19 Relapses, Lack Of Omicron Data Complicate Paxlovid Case In India
CHAI Hints At $25 A Course For Generic
A few cases of COVID-19 relapse have Twitter abuzz about the need for data on Paxlovid’s effectiveness, particularly against the Omicron variant and in vaccinated individuals. Despite regulatory approval in India, the drug has not yet been included in treatment guidelines and a debate on recommended dosage now complicates matters
More from Business
More from Scrip
Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.
• By
China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.
• By
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.